In vitro and physiologically ‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin

ConclusionsIn vitro DDI followed by a predictive or PBPK approach was applied to determine DDI potential of canagliflozin. Overall, canagliflozin is neither a perpetrator nor a victim of clinically important interactions.

Source: British Journal of Clinical Pharmacology - December 19, 2016 Category: Drugs & Pharmacology Authors: Rao N. V. S. Mamidi, Shannon Dallas, Carlo Sensenhauser, Heng Keang Lim, Ellen Scheers, Peter Verboven, Filip Cuyckens, Laurent Leclercq, David C. Evans, Michael F. Kelley, Mark D. Johnson, Jan Snoeys Tags: DRUG INTERACTIONS Source Type: research